GlassScriptPhysician profile
Jose Xavier Pluguez
NPI 1922158476
$1,138.10
in general payments reported to CMS, 2019-2025
21 companies · $520 in 2025
The $520 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.63 · 2020: $20.06 · 2021: $50.40 · 2023: $137 · 2024: $355 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $125.77 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $124.75 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $120.26 | 2019-2025 | Airsupra, Breztri |
| Amgen INC. | $104.00 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.19 | 2023-2025 | Jardiance |
| Abbott Laboratories | $72.49 | 2024-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.04 | 2024-2025 | Xifaxan |
| Chiesi USA, INC. | $70.46 | 2020-2021 | |
| Boston Scientific Corporation | $59.57 | 2025 | General - Therapies |
| Glaxosmithkline, LLC. | $44.31 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $41.13 | 2019 | |
| Hologic Sales and Service, LLC | $33.94 | 2025 | Thinprep 2000 Processor, Aptima |
| Dexcom, INC. | $33.10 | 2023-2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $30.39 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $24.86 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.26 | 2024 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $18.90 | 2025 | Rexulti |
| Pfizer INC. | $17.87 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.43 | 2024 | |
| Shield Therapeutics INC | $14.78 | 2024 | |
| Esperion Therapeutics, INC. | $14.60 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Pluguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.